A Phase 1/2 interventional study of BOLD-100 ± FOLFOX ± Bevacizumab Chemotherapy (Arm VII) and BOLD-100 in combination with FOLFOX Chemotherapy (Arms I-VI) in Colorectal Cancer, Pancreatic Cancer and Gastric Cancers, sponsored by Bold Therapeutics, Inc.. Recruiting at 28 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by Bold Therapeutics, Inc. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 379 studies in Colorectal Neoplasms with a site in Canada — 72 open to participants now, 116 under way, 12 of them phase 3. Colorectal Neoplasms · Canada.
Among the 379 studies in Colorectal Neoplasms with a site in Canada, this one is the 129th largest by planned enrollment of the 324 interventional ones that give a count, is one of 16 that started in 2020, is one of 39 in phase 1/2, reaches primary completion later than 57 of the 115 other live ones, and was the 257th registered.
6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →72 of the 379 studies in Colorectal Neoplasms with a site in Canada are open now. Recruiting first, the newest first:
EMD Serono Research & Development Institute, Inc. · Sites in Canada, United States, Argentina and 16 more countries
Ages 18+
Nova Scotia Health Authority · Sites in Canada
Ages 18+
Incyte Corporation · Sites in Canada, United States, Argentina and 19 more countries
Ages 18+
Bristol-Myers Squibb · Sites in Canada, United States, Argentina and 22 more countries
Ages 18+
Pfizer · Sites in Canada, United States, Argentina and 17 more countries
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
379 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 107 · Phase 2 128 · Phase 3 68 · Phase 4 6
First in 1992; this study’s year is marked. 16 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 220 is above the median of 76 across 4,811 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 151 across the 324 interventional studies, 399 across the 48 observational. Of the 240 that completed or were terminated, 82 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
197 of 379 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Bold Therapeutics, Inc. as lead sponsor.
Bold Therapeutics, Inc. has 1 study filed under Colorectal Neoplasms — fewer than ten, so there is no comparison to draw.
38 of the studies in Colorectal Neoplasms with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04486378BioNTech SEA Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer | 2026-11 |
| NCT02864485University Health Network, TorontoLiving Donor Liver Transplantation for Unresectable Colorectal Cancer Liver Metastases | 2026-11 |
| NCT00335816Memorial Sloan Kettering Cancer CenterRadiation Therapy and Fluorouracil With or Without Combination Chemotherapy Followed by Surgery in Treating Patients With Stage II or Stage III Rectal Cancer | 2026-12 |
| NCT07312786Nova Scotia Health AuthorityTesting the Feasibility of a Virtual Application to Support Breast and Colorectal Cancer Survivors | 2026-12 |
| NCT05843188University Health Network, TorontoStudy of Hydroxychloroquine With FOLFIRI and Bevacizumab in DTP-high Metastatic Colorectal Cancer | 2026-12-24 |
Add all 38 to your calendar (.ics) → With an account.
Among the 379 studies in Colorectal Neoplasms with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
BOLD-100 is an intravenously administered sterile solution containing the ruthenium-based small molecule. BOLD-100 has been shown to preferentially decrease the expression of GRP78 in tumour cells and ER stressed cells when compared to normal cells. BOLD-100 will be combined with cytotoxic FOLFOX ± Bevacizumab chemotherapy in this study, with a dose escalation cohort to ensure tolerability and safety, followed by a cohort expansion phase. This study now includes as a treatment intervention the SOC combination FOLFOX ± Bevacizumab, if indicated.
BOLD-100 is a novel, targeted anti-cancer therapy which is an intravenously administered small molecule drug. In a previous Phase 1 study (NCT01415297) BOLD-100 showed low toxicity with minimal hematological issues as well as some potential anti-tumour activity. The lack of observed hematological toxicity and neurotoxicity position BOLD-100 well for use in combination with a broad range of standard-of-care (SOC) chemotherapy regimens.
This is a prospective, multicenter non-randomized Phase 1b/2a dose escalation \& expanded cohort study of BOLD-100 in patients with advanced gastrointestinal malignancies (colorectal, pancreatic, gastric cancers, and cholangiocarcinoma) receiving standard-of-care FOLFOX chemotherapy. Enrollment in Arms I - VI is closed to enrollment.
Colorectal cancer (ARM VII) for patients who are oxaliplatin naïve and have received only 1 prior line of therapy in the metastatic setting. Within this arm, participants will be randomized to one of two dose levels of BOLD-100 - either 500 mg/m2 or 625 mg/m2 in combination with FOLFOX ± Bevacizumab or FOLFOX alone, in a 1:1:1 ratio. Participants enrolled into Arm VII will complete quality of life questionnaires examining general quality of life and neuropathy associated quality of life parameters. Participants will be eligible to receive the monoclonal antibody Bevacizumab as part of the standard of care treatment regimen (FOLFOX) if indicated.
The criteria were revised on the registry on Oct 28, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Arm closed to enrollment.
Drug: BOLD-100 in combination with FOLFOX Chemotherapy (Arms I-VI)
Arm closed to enrollment.
Drug: BOLD-100 in combination with FOLFOX Chemotherapy (Arms I-VI)
Arm closed to enrollment.
Drug: BOLD-100 in combination with FOLFOX Chemotherapy (Arms I-VI)
Arm closed to enrollment.
Drug: BOLD-100 in combination with FOLFOX Chemotherapy (Arms I-VI)
Arm closed to enrollment.
Drug: BOLD-100 in combination with FOLFOX Chemotherapy (Arms I-VI)
Arm closed to enrollment.
Drug: BOLD-100 in combination with FOLFOX Chemotherapy (Arms I-VI)
Arm open to enrollment. 500 mg/m2 BOLD-100 + SOC (FOLFOX ± Bevacizumab)
Drug: BOLD-100 ± FOLFOX ± Bevacizumab Chemotherapy (Arm VII)
Arm open to enrollment. 625 mg/m2 BOLD-100 + SOC (FOLFOX ± Bevacizumab)
Drug: BOLD-100 ± FOLFOX ± Bevacizumab Chemotherapy (Arm VII)
Arm open to enrollment. FOLFOX ± Bevacizumab alone.
Drug: BOLD-100 ± FOLFOX ± Bevacizumab Chemotherapy (Arm VII)
Arm VIIA: 500 mg/m2 BOLD-100 combined with FOLFOX ± Bevacizumab; Arm VIIB: 625 mg/m2 BOLD-100 combined with FOLFOX ± Bevacizumab; Arm VIIC: FOLFOX ± Bevacizumab alone
BOLD-100 at 625 mg/m2 combined with FOLFOX Chemotherapy
Incidence and severity of adverse events ([S]AEs)
Arms I-VI: Primary outcome measure; Arm VII: Secondary outcome measure
Time frame: Through study completion, approximately 2 weeks after last treatment
Incidence of dose-limiting toxicities (DLT)
Dose escalation only.
Time frame: Screening to 4 weeks after first treatment
Incidence of clinically significant changes or abnormalities from Physical Examinations, ECGs, Vital Signs, Laboratory Results, ECOG performance status
Arms I-VI: Primary outcome measure; Arm VII: Secondary outcome measure
Time frame: Through study completion, approximately 2 weeks after last treatment
Progression Free Survival (PFS): Arm VII
Arm VII: Primary outcome measure
Time frame: Through study completion, approximately 2 weeks after last treatment for last patient
Overall Response Rate (ORR): Arm VII
Arm VII: Primary outcome measure
Time frame: Through study completion, approximately 2 weeks after last treatment for last patient
Overall Survival (OS): Arm VII
Arm VII: Primary outcome measure
Time frame: Through study completion, approximately 2 weeks after last treatment for last patient
Progression Free Survival (PFS): Arms I-VI
Arms I-VI: Secondary outcome measure
Time frame: Through study completion, approximately 2 weeks after last treatment for last patient
Overall Response Rate (ORR): Arms I-VI
Arms I-VI: Secondary outcome measure
Time frame: Through study completion, approximately 2 weeks after last treatment for last patient
Overall Survival (OS): Arms I-VI
Arms I-VI: Secondary outcome measure
Time frame: Through study completion, approximately 2 weeks after last treatment for last patient
Baseline and changes in biomarker levels during treatment
Serum GRP78
Time frame: Arms I-VII; Through study completion, approximately 2 weeks after last treatment
Peak Plasma Concentrations (Cmax)
Arms I-VII
Time frame: Arms I-VII; Through study completion, approximately 2 weeks after last treatment
Area under the plasma concentration versus time (AUC)
Arms I-VII
Time frame: Arms I-VII; Through study completion, approximately 2 weeks after last treatment
Elimination half life (T1/2)
Arms I-VII
Time frame: Arms I-VII; Through study completion, approximately 2 weeks after last treatment
Quality of life evaluation
Arm VII
Time frame: Through study completion, approximately 2 weeks after last treatment
Changes in dose reductions, treatment discontinuations, and interruptions, and AE's reported related to neuropathy from baseline
Arm VII
Time frame: Through study completion, approximately 2 weeks after last treatment
Cancer mutational status in blood and tissue biomarker relationship to clinical outcomes
Circulatory tumor DNA (ctDNA) collection will be tested for a panel of tumor mutations, genomic alterations, microsatellite instability and tumor mutational burden, and these will be associated to clinical outcomes, including overall survival, progression-free survival, overall response rate and other outcome measures
Time frame: Arm VII; Through study completion, approximately 2 weeks after last treatment
GRP78 levels and relationship to clinical outcomes
Optional biopsy samples at screening and at cycle 4 will be collected and analyzed for GRP78 levels, other related pathway markers, immune cell profiles, and cancer mutation profiles, and comparing these to clinical outcomes including overall survival, progression-free survival, overall response rate and other outcome measures
Time frame: Arm VII; Through study completion, approximately 2 weeks after last treatment
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2020 (actual). Primary completion is estimated for Jul 2027, 82 months after the start.
Of 159 industry-sponsored phase 1/2 interventional studies under Colorectal Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 82. This study's planned 82 months is above that.
Counting every sponsor, half of 261 studies reached it within 59 months; a quarter within 36 and three quarters within 87.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 28, 2026: primary completion Jun 2026 → Jul 2027 and completion Sep 2026 → Dec 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.